Gleevec
Gleevec Brand names, Gleevec Analogs
Gleevec Brand Names Mixture
- No information avaliable
Gleevec Chemical_Formula
C29H31N7O
Gleevec RX_link
http://www.rxlist.com/cgi/generic3/gleevec.htm
Gleevec fda sheet
Gleevec msds (material safety sheet)
Gleevec Synthesis Reference
No information avaliable
Gleevec Molecular Weight
493.603 g/mol
Gleevec Melting Point
226 oC (mesylate salt)
Gleevec H2O Solubility
Very soluble in water at pH < 5.5 (mesylate salt)
Gleevec State
Solid
Gleevec LogP
3.218
Gleevec Dosage Forms
Capsule; Tablet
Gleevec Indication
For the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML). Also indicated for the treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. Also indicated with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
Gleevec Pharmacology
Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.
Gleevec Absorption
Imatinib is well absorbed with mean absolute bioavailability is 98% with maximum levels achieved within 2-4 hours of dosing
Gleevec side effects and Toxicity
Side effects include nausea, vomiting, diarrhea, loss of appetite, dry skin, hair loss, swelling (especially in the legs or around the eyes) and muscle cramps
Gleevec Patient Information
Gleevec Organisms Affected
Humans and other mammals
